-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The TITAN trial is a randomized, placebo-controlled phase 3 trial.
This article reports the final efficacy and safety analysis results of the placebo group after the trial was unblinded and crossover to the apalutamide group.
This article reports the final efficacy and safety analysis results of the placebo group after the trial was unblinded and crossover to the apalutamide group.
In this trial, a total of 1052 mCSPC patients were randomly divided into two groups 1:1 and received apalutamide (240 mg QD) or placebo combined with ADT.
The median follow-up was 44.
The median duration of treatment for apalutamide, placebo, and cross-treatment were 39.
Prognostic analysis
Prognostic analysisCompared with placebo, apalutamide combined with ADT treatment can significantly reduce the risk of death (35% reduction; median OS: less than 52.
Compared with placebo, apalutamide combined with ADT treatment can significantly reduce the risk of death.
Adverse events
Adverse eventsApalutamide combined with ADT can also prolong minor progression-free survival and castration resistance (both p<0.
In summary, the final results of the TITAN trial proved that even if there is a crossover between the intervention groups, apalutamide combined with ADT treatment can improve the OS of mCSPC patients, delay the onset of castration resistance, maintain health-related quality of life , and be safe Sex can be.
Apalutamide combined with ADT treatment can improve the OS of mCSPC patients, delay the onset of castration resistance, and maintain health-related quality of life.
Original source:
Chi Kim N, Chowdhury Simon, Bjartell Anders et al.
org/doi/figure/10.
1200/JCO.
20.
03488" target="_blank" rel="noopener">Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study
in this message
